Preclinical and Clinical Practice of S-1 in Japan

摘要: Recently, there has been an increased demand more effective therapy cancer patients. To satisfy this demand, attempts have made to develop novel drugs or establish combination therapies with a new mechanism of action concept in the field chemotherapy. A number anticancer chemical entities introduced into clinical practice since discovery 5-fluorouracil (5-FU) by Heidelberger et al. 1957 (1). However, none satisfied our demands, and concern about whether chemotherapy is against persistent. In chapter, we provide review on history date concurrently refer oral agent, S-1, through detailed description thereof from development results; drug proving preclinical theories setting Japan, validating self-rescue (SRC)—a conceptual goal as treatment modality that simultaneously dual action, i.e., enhancement 5-FU effects alleviation 5-FU-induced adverse reactions, which groped for last 15 yr.